Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID

Abstract:

Background: Mechanisms underlying persistent cardiopulmonary symptoms following SARS-CoV-2 infection (post-acute sequelae of COVID-19 “PASC” or “Long COVID”) remain unclear. This study sought to elucidate mechanisms of cardiopulmonary symptoms and reduced exercise capacity.

Methods: We conducted cardiopulmonary exercise testing (CPET), cardiac magnetic resonance imaging (CMR) and ambulatory rhythm monitoring among adults > 1 year after confirmed SARS-CoV-2 infection in a post-COVID cohort, compared those with or without symptoms, and correlated findings with previously measured biomarkers.

Results: Sixty participants (median age 53, 42% female, 87% non-hospitalized) were studied at median 17.6 months following SARS-CoV-2 infection. On CPET, 18/37 (49%) with symptoms had reduced exercise capacity (<85% predicted) compared to 3/19 (16%) without symptoms (p = 0.02). Adjusted peak VO2 was 5.2 ml/kg/min lower (95%CI 2.1-8.3; p = 0.001) or 16.9% lower percent predicted (95%CI 4.3-29.6; p = 0.02) among those with symptoms. Chronotropic incompetence was common. Inflammatory markers and antibody levels early in PASC were negatively correlated with peak VO2 more than 1 year later. Late-gadolinium enhancement on CMR and arrhythmias were absent.

Conclusions: Cardiopulmonary symptoms >1 year following COVID-19 were associated with reduced exercise capacity, which was associated with elevated inflammatory markers early in PASC. Chronotropic incompetence may explain exercise intolerance among some with cardiopulmonary Long COVID.

Source: Durstenfeld MS, Peluso MJ, Kaveti P, Hill C, Li D, Sander E, Swaminathan S, Arechiga VM, Lu S, Goldberg SA, Hoh R, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Kelly JD, Glidden DV, Henrich TJ, Martin JN, Lee YJ, Aras MA, Long CS, Grandis DJ, Deeks SG, Hsue PY. Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID. J Infect Dis. 2023 May 11:jiad131. doi: 10.1093/infdis/jiad131. Epub ahead of print. PMID: 37166076. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad131/7159960 (Full text available as PDF file)

Post-acute Sequelae of SARS Co-V2 and Chronic Fatigue/Myalgic Encephalitis Share Similar Pathophysiologic Mechanisms of Exercise Limitation

Abstract:

Abstract available online: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A6470

Source: S. Jothi, G. Claessen, M. Insel, S. Kubba, E. Howden, S.-R. Carmona, F.P. Rischard. Post-acute Sequelae of SARS Co-V2 and Chronic Fatigue/Myalgic Encephalitis Share Similar Pathophysiologic Mechanisms of Exercise Limitation. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A6470

ME/CFS Pathophysiology Investigated by Invasive Cardiopulmonary Exercise Testing and Autonomic Function Testing

Abstract

Introduction: Mechanisms underlying exercise and orthostatic intolerance in myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS) have been uncovered by invasive cardiopulmonary exercise testing (iCPET) and
autonomic function testing (AFT), but the relationships between the two are not known. This study aims to determine
if there is overlap of cardiovascular and respiratory pathophysiology in patients who have undergone both
tests.

Methods: Between January 2017 and April 2022, 62 patients were identified with a contemporary iCPET and
AFT. Key variables from the iCPET included peak oxygen uptake (pVO2), cardiac output (pQc), right atrial pressure
(pRAP), and systemic oxygen extraction (Ca-vOy/Hgb) at peak exercise. Key variables from the autonomic testing
included epidermal and sweat gland small fiber neurite density, electrochemical skin conductance, and change in
heart rate (AH) and end tidal carbon dioxide (AETCO2) from supine to upright during the tilt table test
(TTT).

Results: All 62 patients demonstrated preload failure (pRAP < 6.5mmHg). Of this group, 54 patients (87.1%) fulfilled NAM criteria for ME/CFS, with 32 testing positive (59.3%) for small fiber neuropathy (SFN) using either morphological and/or functional testing. Significant correlations were found between pVOg and both AH (r=-0.439. P<0.05) and AETCO, (r=0.474, P<0.05) during TTT. The same tilt table variables were found to be significantly correlated with pQc (r=-0.365, P<0.05 and r=0.351, P<0.05) from the iCPET. It should be noted that 8 of the ME/CFS SFN patients (25%) fulfilled diagnostic criteria for postural orthostatic tachycardia syndrome (POTS) based on the tilt table test.

Conclusion: Decreased oxygen uptake and cardiac output at peak exercise during iCPET correlated with a greater change in heart rate and ETCO from supine to upright during TTT. There appears to be significant overlap of cardiopulmonary pathophysiology in ME/CFS underlying exercise and orthostatic symptoms.

Source: J. Squires, K. Wichmann Madsen, M.C. Stovall, S. Al-Zayer, W. Xiao, C.-J. Chang, P. Novak, D.M. Systrom. ME/CFS Pathophysiology Investigated by Invasive Cardiopulmonary Exercise Testing and Autonomic Function Testing. American Journal of Respiratory and Critical Care Medicine 2023;207:A2996. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A2996

Sex Differences in Hemodynamic Response to Exercise in Patients With Myalgic Encephalomyelitis: Insights From Invasive Cardiopulmonary Exercise Testing

Abstract:

Abstract available online: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A2995

Source: K. Wichmann Madsen, J. Squires, M.C. Stovall, S. Al-Zayer, C.-J. Chang, W. Xiao, R. Pari, P. Joseph, D.M. Systrom. Sex Differences in Hemodynamic Response to Exercise in Patients With Myalgic Encephalomyelitis: Insights From Invasive Cardiopulmonary Exercise Testing. American Journal of Respiratory and Critical Care Medicine 2023;207:A2995 https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A2995

A Mixed Methods System for the Assessment of Post Exertional Malaise in Encephalomyelitis/Chronic Fatigue Syndrome

Abstract:

Background A central feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is post exertional malaise (PEM), which is an acute worsening of symptoms after a physical, emotional and/or mental exertion. PEM is also a feature of Long COVID. Dynamic measures of PEM have historically included scaled questionnaires which have not been validated in ME/CFS. To enhance our understanding of PEM and how best to measure it, we conducted semi-structured qualitative interviews (QIs) at the same intervals as Visual Analog Scale (VAS) measures after a Cardiopulmonary Exercise Test (CPET).

Methods Ten ME/CFS and nine healthy volunteers participated in a CPET. For each participant, PEM symptom VAS (7 symptoms) and semi-structured QIs were administered at six timepoints over 72 hours before and after a single CPET. QI data were used to plot the severity of PEM at each time point and identify the self-described most bothersome symptom for each patient. QI data were used to determine the symptom trajectory and peak of PEM. Performance of QI and VAS data were compared to each other using Spearman correlations.

Results QIs documented that each ME/CFS volunteer had a unique PEM experience, with differences noted in the onset, severity, trajectory over time, and most bothersome symptom. No healthy volunteers experienced PEM. Scaled QI data were able to identify PEM peaks and trajectories, even when VAS scales were unable to do so due to known ceiling and floor effects. QI and VAS fatigue data corresponded well prior to exercise (baseline, r=0.7) but poorly at peak PEM (r=0.28) and with the change from baseline to peak (r=0.20). When the most bothersome symptom identified from QIs was used, these correlations improved (r=.0.77, 0.42. and 0.54 respectively) and reduced the observed VAS scale ceiling and floor effects.

Conclusion QIs were able to capture changes in PEM severity and symptom quality over time in all the ME/CFS volunteers, even when VAS scales failed to do so. Information collected from QIs also improved the performance of VAS. Measurement of PEM can be improved by using a quantitative-qualitative mixed model approach.

Disclaimer This research/work/investigator was supported (in part) by the Division of Intramural Research of the National Institutes of Health, NINDS. The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the National Institutes of Health.

Source: Barbara StussmanBrice CalcoGina NoratoAngelique GavinSnigdha ChigurupatiAvindra NathBrian Walitt. A Mixed Methods System for the Assessment of Post Exertional Malaise in Encephalomyelitis/Chronic Fatigue Syndrome.

Lung diffusing capacities for nitric oxide and carbon monoxide at rest and post-walking in long COVID

Abstract:

Background: Approximately one-third of long coronavirus disease 2019 (long COVID) patients report breathlessness and fatigue even during activities of daily living. We hypothesised that abnormalities of combined diffusing capacity of the lung for nitric oxide (D LNO) and carbon monoxide (D LCO) at rest or after mild exercise are associated with breathlessness in patients with long COVID.

Methods: Single-breath combined D LNO and D LCO were measured at rest and immediately after a short bout of treadmill exercise simulating ordinary walking in 32 Caucasian patients with long COVID and dyspnoea at rest. 20 subjects served as a control group.

Results: At rest, combined D LNOD LCO and alveolar volume (V A) were significantly lower in long COVID than in controls, with D LNO and D LCO being below the limits of normal in 69% and 41% of cases, respectively. Mean values of D LNO/V A and D LCO/V A in long COVID patients were less than controls, yet, in only 22% and 12% of long COVID patients were the values of D LNO/V A and D LCO/V A below the limits of normal. After treadmill exercise, D LNOD LNO/D LCOV A and heart rate increased significantly without differences between groups. D LNO remained below the limit of normal in 47% of long COVID patients.

Conclusion: These data suggest localised discrete loss of lung units in approximately half of long COVID patients, not completely explained by loss of V A or of alveolar-capillary recruitment during exercise.

Source: Barisione G, Brusasco V. Lung diffusing capacities for nitric oxide and carbon monoxide at rest and post-walking in long COVID. ERJ Open Res. 2023 Apr 17;9(2):00363-2022. doi: 10.1183/23120541.00363-2022. PMID: 37070120; PMCID: PMC9638122. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638122/ (Full text)

Exercise Intolerance Associated with Impaired Oxygen Extraction in Patients with Long COVID

Abstract:

Objective: Chronic mental and physical fatigue and post-exertional malaise are the more debilitating symptoms of long COVID-19. The study objective was to explore factors contributing to exercise intolerance in long COVID-19 to guide development of new therapies. Exercise capacity data of patients referred for a cardiopulmonary exercise test (CPET) and included in a COVID-19 Survivorship Registry at one urban health center were retrospectively analyzed.

Results: Most subjects did not meet normative criteria for a maximal test, consistent with suboptimal effort and early exercise termination. Mean O2 pulse peak % predicted (of 79 ± 12.9) was reduced, supporting impaired energy metabolism as a mechanism of exercise intolerance in long COVID, n=59. We further identified blunted rise in heart rate peak during maximal CPET. Our preliminary analyses support therapies that optimize bioenergetics and improve oxygen utilization for treating long COVID-19.

Source: Norweg A, Yao L, Barbuto S, Nordvig AS, Tarpey T, Collins E, Whiteson J, Sweeney G, Haas F, Leddy J. Exercise Intolerance Associated with Impaired Oxygen Extraction in Patients with Long COVID. Respir Physiol Neurobiol. 2023 Apr 17;313:104062. doi: 10.1016/j.resp.2023.104062. Epub ahead of print. PMID: 37076024; PMCID: PMC10108551. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108551/ (Full text)

Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-Acute Sequelae of SARS-CoV-2: More in Common Than Not?

Abstract:

Topic importance: Post-Acute Sequelae of SARS-CoV-2 (PASC) is a long-term consequence of acute infection from coronavirus disease 2019 (COVID-19). Clinical overlap between PASC and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been observed, with shared symptoms including intractable fatigue, postexertional malaise, and orthostatic intolerance. The mechanistic underpinnings of such symptoms are poorly understood.

Review findings: Early studies suggest deconditioning as the primary explanation for exertional intolerance in PASC. Cardiopulmonary exercise testing (CPET) reveals perturbations related to systemic blood flow and ventilatory control associated with acute exercise intolerance in PASC, which are not typical of simple detraining. Hemodynamic and gas exchange derangements in PASC have substantial overlap with those observed with ME/CFS, suggestive of shared mechanisms.

Summary: This review aims to illustrate exercise pathophysiologic commonalities between PASC and ME/CFS that will help guide future diagnostics and treatment.

Source: Joseph P, Singh I, Oliveira R, Capone CA, Mullen MP, Cook DB, Stovall MC, Squires J, Madsen K, Waxman AB, Systrom DM. Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-Acute Sequelae of SARS-CoV-2: More in Common Than Not? Chest. 2023 Apr 11:S0012-3692(23)00502-0. doi: 10.1016/j.chest.2023.03.049. Epub ahead of print. PMID: 37054777; PMCID: PMC10088277. https://pubmed.ncbi.nlm.nih.gov/37054777/

Graded exercise therapy and cognitive behavior therapy do not improve employment outcomes in ME/CFS

1 Introduction:

In a 1989 article, Wessely et al. [1] proposed a model of the onset and perpetuation of chronic fatigue syndrome, the illness often called myalgic encephalomyelitis and now frequently referred to as ME/CFS. In this model, patients’ symptoms were attributed to the effects of deconditioning following an acute illness. The symptoms were said to be perpetuated by patients’ persistent but purportedly unwarranted conviction that they continued to suffer from a medical disease that was exacerbated by exertion. The proposed treatment strategy combined gradual increases in activity to reverse the presumed deconditioning with efforts to alter patients’ supposedly misguided perceptions about their ailment.

ME/CFS has long been associated with marked disability and long-term sickness absences [2], with estimated rates of unemployment among patients ranging from 35% to 69% [3]. From the start, the promotion of behavioral and psychological rehabilitation has been intertwined with questions about whether ME/CFS patients with limited capacity to work should be able to receive some form of income or disability support. In a section on “sickness benefits” in the 1989 paper [1], the authors argued that decisions about social welfare payments should be linked to patients’ willingness to undergo behavioral and psychological interventions. “It is reasonable to expect a patient to cooperate with treatment before being labelled as chronically disabled,” noted the authors, notwithstanding the theoretical and unproven status of their model.

This rehabilitative approach achieved dominance over the next couple of decades, not only in the UK but in the US and many other countries. Graded exercise therapy (GET) and an illness-specific form of cognitive behavior therapy (CBT) became the predominant and most heavily researched ME/CFS interventions and were enshrined in multiple clinical guidelines. A 2005 review of the natural history of the illness [4], which found that only 5% of patients fully recovered spontaneously, noted “increasing evidence” for GET and CBT and therefore advised that “medical retirement should be postponed until a trial of such treatment has been given.”

While many studies have included employment status as a demographic data point [2, 3], fewer have specifically examined the relationship between GET and CBT and employment-related outcomes. Nonetheless, the results from the latter group are consistent and clear: The interventions do not lead to improved outcomes in employment status [5–13].

This question has taken on renewed urgency given the overlaps between ME/CFS and the phenomenon known as long Covid, or more formally as post-acute sequelae of SARS CoV-2 (PASC). A significant proportion of patients with prolonged symptoms after a coronavirus infection appear to suffer from the same cluster of symptoms that characterize ME/CFS, including pronounced exhaustion, relapses after minimal exertion known as post-exertional malaise (PEM), cognitive impairments, and orthostatic intolerance, among others. Like ME/CFS patients, many of this new PASC cohort have found that they are unable to sustain their previous level of employment. While the similarities between the two conditions have been widely noted by clinicians and medical investigators, they have also led to efforts to promote the traditional ME/CFS rehabilitation paradigm for this large wave of post-viral patients.

2 Employment outcomes in the PACE trial

After gaining momentum during the 1990 s and 2000 s, the GET/CBT approach was significantly reinforced with the 2011 publication in the Lancet of the first results of the PACE trial, the largest study of the two interventions for ME/CFS [5]. Additional PACE results were published in 2012 and 2013 [6, 7]. The study was partially funded by the UK’s Department for Work and Pensions (DWP). Officials at the agency presumably believed or hoped that the trial would provide robust data to support the use of these two strategies.

The PACE investigators presumably hoped for that as well; key members of the team maintained strong links with disability insurance companies, advising them that GET and CBT were effective in helping this group of challenging patients recover. In a 2002 essay for a UNUMProvident report on trends in disability [14], Michael Sharpe, a lead PACE investigator, wrote that “symptoms and disability” in patients with unexplained conditions “are shaped by psychological factors,” and in particular by “patients’ beliefs and fears.” He suggested that the promotion of biological disease models by ME/CFS patient advocates could impact health outcomes among insurance claimants.

Commenting on how public messaging and related “social factors” influenced the course of illness for these patients, Sharpe wrote: “Relevant factors include the information patients receive about the symptoms and how to cope with them. This information may be helpful or may stress the chronicity of the illness and promote helplessness. Such unhelpful information is found in “self-help” (!) books and increasingly on the Internet (see for example www.meassociation.org.uk)…Other social factors that perpetuate illness are anger with the person or organisation the illness is attributed to, or toward the insurer for not believing them.” In the article, Sharpe further argued that receiving financial benefits ultimately discouraged such claimants from getting better.

However, the data from PACE did not provide evidence that GET and CBT were effective in helping ME/CFS patients in the employment domain [6]. With 641 participants, PACE was the largest treatment trial for ME/CFS [5]. The investigators themselves referred to it as the “definitive” test of the two interventions [15]. In touting it as a success, they reported that around 60% had improved and 22% had recovered after treatment with GET and CBT, much more than in the other groups [5, 7]. However, these positive findings were all from subjective, self-reported measures. When such measures are paired with unblinded treatments, as in the PACE trial, they are subject to an unknown amount of bias.

PACE also included an employment measure as one of four objective outcomes, along with whether or not the participant was receiving social welfare or disability benefits, a step-test to assess fitness, and a six-minute-walking test. The results were uniformly poor. The first three measures produced null findings across the board, with no advantages conferred by the interventions [6, 7]; in the six-minute walking test, the GET group showed a statistically significant but clinically insignificant improvement [5]. In terms of employment, the percentage of participants in the GET group reporting lost days of work increased from 83% at baseline to 86% at 12 months after randomization; in the CBT group, the percentage was 84% both before and after treatment. In all study arms, the percentage of participants receiving unemployment or disability benefits was higher after treatment [6].

In promoting GET and CBT as effective, the PACE authors downplayed the findings on employment, receipt of disability or unemployment support, and other objective results, suggesting these should be ignored when determining whether patients had improved and recovered. In correspondence, they challenged the reliability and even the objectivity of the measures they themselves had pre-designated as objective. As they wrote: “Recovery from illness is a health status, not an economic one, and plenty of working people are unwell, while well people do not necessarily work. Some of our participants were either past the age of retirement or were not in paid employment when they fell ill. In addition, follow-up at 6 months after the end of therapy may be too short a period to affect either benefits or employment.” [16].

It is indisputable that other factors besides health status play a role in employment outcomes. Nonetheless, if the PACE trial’s reported results of significant improvement and recovery were accurate, then a measurable benefit from GET and CBT in employment and in the receipt of financial support would have been expected. As has been well-documented, the investigators weakened key subjective outcome measures in ways that dramatically improved their reported results; published re-analyses of trial data have found that no one achieved “recovery” from either of the therapies, and rates of improvement were so marginal that they were likely due to bias and expectation effects [17, 18]. Given these findings, the similarly disappointing results for employment outcomes in PACE should not be surprising.

3 Other studies on CBT/GET and employment outcomes

In a review of treatment studies that included employment outcomes, Vink and Vink-Niese [8] found that the standard interventions did not have an overall positive effect on work status. Besides PACE, among the studies reviewed were two other randomized trials and five observational studies based on data from clinical services. The two other trials, one in the Netherlands with 278 participants and one in England with 153, both investigated CBT and reported no statistically significant differences in employment outcomes between the intervention and control groups [9, 10]. The largest observational study included 952 patients seeking care at specialty clinics in England, although a great many did not provide post-treatment outcomes; among a subgroup of 394, 18% reported having returned to work or increased work hours, while 30% reported having stopped work or reduced work hours [11]. According to a Belgian report, a review of 655 patients attending domestic clinics found that “employment status decreased” when assessed after treatment while the percentage of those “living from a sickness allowance” rose from 54% to 57% [12].

Other observational research had similarly unpromising findings. In the most recent study, Stevelink et al. [13], of 508 patients who attended clinical services between 2007 and 2014, only 316 provided information about post-treatment employment status, among other measures. Of those, 9% had returned to work after not having worked at baseline. On the other hand, 6% had stopped working after having been working at baseline, leaving a net return-to-work after treatment of just 3%–a handful of people. Moreover, that figure is likely to be overstated, given the high loss-to-follow-up from the initial sample of 508. The drop-outs were more seriously ill at baseline, so they might be expected to have worse employment outcomes than those who ended up providing data at the final time point.

According to the authors, “unhelpful beliefs such as fear of activity and exercise and concerns about causing damage, combined with all or nothing behaviour and behavioural avoidance, were associated with not working” [13]. This statement is problematic because “fear of activity,” “concerns about causing damage” and related indications of caution should be considered reasonable and prudent perspectives, not “unhelpful beliefs,” among patients with the core ME/CFS symptom of PEM. Beyond that, the study itself documented little or no change after treatment in the domains of “fear-avoidance,” “catastrophizing,” “embarrassment avoidance,” “symptom focusing,” “all-or-nothing behaviour,” and “avoidance/resting behaviour,” even though such factors were “specifically targeted in CBT and, to some extent, GET.”

Moreover, the authors reported no change in subjective fatigue scores, and only a marginal increase in subjective physical function scores, with participants remaining seriously disabled even after treatment. Thus, although the authors noted correctly that “meaningful occupation is important for well-being and psychosocial needs,” their study documented that their approach failed to impact factors presumed to be essential to helping participants achieve that important goal. (Since Stevelink et al’s senior author was one of the lead PACE investigators, it is unclear why the paper did not mention the null employment results from that “definitive” study.)

The theoretical illness model underlying all of these studies is essentially the one outlined by Wessely et al. more than three decades ago [1]. That illness model is at odds with the extensive physiological abnormalities that have been found in ME/CFS [17, 19]. Research findings have also undermined two core assumptions of the model–specifically, that ME/CFS patients are deconditioned and have an unwarranted fear of activity or exercise. [20–22]. In 2017, the US Centers for Disease Control and Prevention dropped its recommendations for GET and CBT as ME/CFS treatments. In 2021, the UK National Institute for Health and Care Excellence (NICE) reversed its earlier support for the interventions in new ME/CFS guidelines; in its analysis, NICE assessed the quality of the evidence supporting GET and CBT as either “very low” or merely “low” [23]. These developments are consistent with the failure of GET and CBT to lead to improved employment outcomes in PACE and other studies.

4 Conclusion

In a recent study of employment status among clinic attendees, Stevelink et al. [13] wrote that “work-related outcomes should be targeted” in treatment for ME/CFS. It is certain that people with ME/CFS experience disrupted occupational lives and that it would be desirable to identify treatments that could restore their full capacity for employment. However, the most common behavioral and psychological interventions— that is, GET and CBT–have already been tested sufficiently to reach a conclusive assessment that they do not lead overall to meaningful improvements in work status. These poor results are consistent across randomized trials, including the high-profile and “definitive” PACE study, as well as observational studies of patients seeking clinical services for their illness.

Some investigators and medical experts continue to promote GET and CBT as treatments for ME/CFS patients based on subjective findings from flawed studies. They also seek to extend these recommendations to patients with long Covid, or PASC, many of whom are receiving ME/CFS diagnoses and facing employment challenges. It is time to state the obvious: The objective data on work outcomes indicate that GET and CBT do not lead to readily apparent benefits in this domain. In consequence, they should no longer be recommended to ME/CFS patients as a strategy for achieving occupational rehabilitation and related benefits.

Source: Tuller D, Vink M. Graded exercise therapy and cognitive behavior therapy do not improve employment outcomes in ME/CFS. Work. 2023 Mar 10. doi: 10.3233/WOR-220569. Epub ahead of print. PMID: 36911962. https://content.iospress.com/articles/work/wor220569 (Full text)

Sex differences in post-exercise fatigue and function in myalgic encephalomyelitis/chronic fatigue syndrome

Abstract:

To assess biobehavioral sex differences in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) utilizing a low burden exercise protocol, 22 females and 15 males with ME/CFS and 14 healthy controls underwent two six-min walk tests.

Fifteen daily assessments were scheduled for fatigue and function ratings and heart monitoring. Six-min walk tests were conducted on days 8 and 9. The ME/CFS group showed high self-report fatigue and impaired physical function, whereas healthy controls did not show fatigue or function abnormalities.

In patients, no significant post-exercise changes were found for heart rate variability (HRV); however, heart rate decreased in ME/CFS males from Day 14 to Day 15 (p = 0.046). Female patients showed increased fatigue (p = 0.006) after the initial walk test, but a downward slope (p = 0.008) in fatigue following the second walk test. Male patients showed a decrease in self-report work limitation in the days after exercise (p = 0.046). The healthy control group evidenced a decrease in HRV after the walk tests from Day 9-14 (p = 0.038).

This pilot study did not confirm hypotheses that females as compared to males would show slower exercise recovery on autonomic or self-report (e.g. fatigue) measures. A more exertion-sensitive test may be required to document prolonged post-exertional abnormalities in ME/CFS.

Trial registration: NCT NCT03331419.

Source: Friedberg F, Adamowicz JL, Bruckenthal P, Milazzo M, Ramjan S, Zhang X, Yang J. Sex differences in post-exercise fatigue and function in myalgic encephalomyelitis/chronic fatigue syndrome. Sci Rep. 2023 Apr 3;13(1):5442. doi: 10.1038/s41598-023-32581-w. PMID: 37012343. https://www.nature.com/articles/s41598-023-32581-w (Full text)